Astrazeneca (AZN) Total Current Liabilities (2009 - 2026)

Astrazeneca (AZN) has reported Total Current Liabilities for 18 consecutive years, with -$32.6 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Current Liabilities fell 11.81% year-over-year to -$32.6 billion; the TTM figure through Mar 2026 stood at -$32.6 billion (down 11.81% YoY), while the FY2025 annual figure was -$30.6 billion, down 209.87% from the prior year.
• Total Current Liabilities came in at -$32.6 billion for Q1 2026 at Astrazeneca, down from -$30.6 billion in the prior quarter.
• The five-year high for Total Current Liabilities was $30.5 billion in Q4 2023, with the low at -$34.1 billion in Q3 2025.
• Average Total Current Liabilities over 5 years is -$18.1 billion, with a median of -$26.4 billion recorded in 2023.
• Across the five-year window, Total Current Liabilities climbed 16.37% in 2022 and plunged 209.87% in 2025, its largest moves.
• Year by year, Total Current Liabilities stood at $26.3 billion in 2022, then increased by 16.16% to $30.5 billion in 2023, then decreased by 8.76% to $27.9 billion in 2024, then slumped by 209.87% to -$30.6 billion in 2025, then retreated by 6.38% to -$32.6 billion in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered -$32.6 billion, -$30.6 billion, and -$34.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.